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Effects of Pioglitazone on Cardiovascular performance in 
both Type I and Type II Diabetes Mellitus (65 p p ) .
Director: Charles L. Eyer, Ph.D.
Effects of pioglitazone on cardiovascular function were 
evaluated in both Type I and Type II diabetic animal models. 
Sprague Dawley rats and Zucker Diabetic Fatty rats were used 
in Type I and Type II diabetes studies respectively.
Pioglitazone treatment increased the body weight and 
decreased the blood glucose levels in Type II diabetic 
animals, but did not alter either body weight or blood 
glucose levels in both control and Type I diabetic animals. 
Pioglitazone treatment did not alter the glycosylated 
hemoglobin values either in control or Type I diabetic rats.
Maximal contractile response to norepinephrine (NE) and 
potassium chloride (KCl) was decreased by pioglitazone in 
Type II diabetic and control animals. In Type I diabetic 
animals, vascular reactivity to KCl was decreased with 
pioglitazone treatment, but vascular reactivity to NE was 
unaltered. Combination of insulin and pioglitazone or 
insulin alone did not show any effects on vascular 
reactivity to NE. Pioglitazone treatment decreased the 
endothelial dependent relaxation in control animals, but 
endothelial independent relaxation was unaltered in both 
control and diabetic rats.
Coronary flow and double product were decreased in Type 
I diabetic animals. Pioglitazone administered to diabetic 
rats (DP) showed the highest mortality and the lowest values 
of heart rate, left ventricular developed pressure (LVDP), 
coronary flow and double product. Insulin treatment 
normalized the cardiac function in Type I diabetic animals, 
and also, the combination of insulin and pioglitazone 
treatment normalized the LVDP and double product in Type I 
diabetic animals.
The results of the present study suggests that the 
severity of myocardial ischemia and reperfusion (MI/R) 
injury is identical in both Type I diabetic and control 
animals. Neither pioglitazone nor insulin treatment 
protected against MI/R injury in either control or diabetic 
rats.
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INTRODUCTION
Diabetea Mellitus:
Diabetes mellitus has been recognized from antiquity. 
Indian and Chinese medical writings mentioned a syndrome of 
polyphagia, polydipsia, polyuria and glycosuria. As early 
as 1869, Langerhans, while still a medical student, 
described the pancreatic islet cells which now bear his 
name.
Diabetes mellitus is a disease of worldwide 
distribution. It is more frequent in some countries than 
others. In the United States there are approximately 14 
million people with diabetes mellitus, close to seven 
percent of the population. As early as 1936, Himsworth 
suggested the existence of at least two forms of diabetes 
(Himsworth, 1936). However, the two types were not 
confirmed until the development of a bioassay for plasma 
insulin. It is well known that the disease is divided into 
two major subtypes. Type I (Insulin-Dependent Diabetes 
Mellitus) and Type II (Noninsulin-Dependent Diabetes 
Mellitus)(Weir et a l . 1986; Lipson, 1986). Both types of 
diabetes are characterized by fasting hyperglycemia and 
glucose intolerance to a glucose challenge. However, the 
pathologies of the two appear to be distinctly different. 
Type I diabetes generally occurs in younger persons and is 
due to the loss of insulin production because of autoimmune 
destruction directed specifically towards the insulin
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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producing islet beta cells. The bulk of evidence indicates 
that autoreactive T lymphocytes initiate and oversee this 
beta cell specific immune destruction (Eisenbarth, 1986).
In contrast. Type XI diabetes is seen most frequently in 
older and overweight people and is associated with either 
dysfunction of insulin secretion, peripheral insulin 
resistance, or both (Van d'Heim et a l . 1990).
Diabetes and Vascular Sensitivitys
Diabetics of either type are known to develop vascular 
complications which contribute to retinopathy (Robison et 
âi» 1986), nephropathy, myopathy (Dvornik, 1987) and 
accelerated atherosclerosis (Christlieb, 1973).
Hyperglycemia is believed to be the major cause of diabetic 
vascular complications involving both macro and 
microvessels. It is unclear how hyperglycemia alters the 
metabolism and functions of vascular cells, although changes 
in nonenzymatic protein glycosylation, accumulation of 
intracellular sorbitol, and reduction of myo-inositol levels 
may be involved (Kennedy and Baynes, 1984; Greene et a l . 
1987) . Weidmann et al (1979) suggested that some diabetic 
vasculopathies are a consequence of altered sensitivity to 
neurotransmitters and circulating neurohormones.
Investigators have attempted to assess the reactivity 
of the cardiovascular system in vivo in experimental 
diabetic rats. Christlieb (1974) observed an increased 
blood pressure response to infused angiotensin II and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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norepinephrine in alloxan-diabetic rats. Kawashima et al 
(1978) demonstrated that STZ-diabetic rats were 
hypertensive. However, Jackson and Carrier (1980) and 
Kohler et al (1980) have demonstrated that STZ-diabetic rats 
are hypotensive 4-6 weeks after injection of the diabetogen 
and the blood pressure responses to norepinephrine (NE) and 
angiotensin XI were blunted. Discrepancies observed in the 
literature may be related to the differences in the species 
of diabetic animals studied and the severity of the disease 
process.
Abnormal vascular reactivity to several vasoactive 
agents has been reported in chemically-induced in vitro 
diabetic animal experiments. The results of experiments in 
which vascular smooth muscle contractility to NE has been 
examined fall into two categories. First, in aortic 
preparations from diabetic rodents, diabetes was associated 
with a decreased maximal response and either no change or a 
decreased EC 50 value (Sullivan and Sparks, 1978; Pfaffman 
et a l . 1982; Turlapaty et a l . 1980). In contrast to the 
above observations, an increased maximal response to NE in 
aortic preparations from diabetic rats has been demonstrated 
by two other groups (Brody and Dixon, 1964; Owen and 
Carrier, 1985). Enhanced responses to selective alpha 1 and 
alpha 2 adrenergic agonists were demonstrated in aortas 
isolated from STZ-diabetic rats (Scarborough and Carrier, 
1983 & 1984). MacLeod and McNeill (1985) found no change in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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vascular reactivity to norepinephrine seven days after the 
onset of digkbetes. However, 100 days after the onset of 
diabetes, they found an increased maximal contractile 
response to NE.
An increased vascular contractile response to the 
membrane depolarization by KCl has been reported in aortas 
isolated from STZ-induced diabetic animals (Owen and 
Carrier, 1979 & 1980). In contrast, other investigators 
have reported either decreased or unaltered vascular 
reactivity to KCl in aortas isolated from STZ diabetic rats. 
No data on vascular reactivity to NE and KCl in non-insulin 
dependent diabetic (Type XI) have been reported.
Many factors play a role in the regulation of vascular 
muscle reactivity and tone. Calcium is critical for the 
initiation of contraction in vascular smooth muscle (Bohr, 
1964) . The contractile response to NE has been resolved 
into two components. The first component is attributed to 
the release of intracellular calcium from the sarcoplasmic 
reticulum and the second component is associated with influx 
of extracellular calcium (Karaki and Weiss, 1984). Enhanced 
vascular contraction in diabetes apparently results from an 
increased responsiveness to extracellular calcium (White and 
Carrier, 1988 & 1990; Sakai and Honda, 1987).
It is possible that increased responsiveness to 
norepinephrine in diabetes might be caused, at least in 
part, by denervation supersensitivity of the vasculature.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Denervation supersensitivity has been demonstrated after 
surgical or chemical sympathectomy (Winguist and Bevan,
1979). Although changes in receptors may be involved 
(Davies et a l . 1982), the decrease in neuronal uptake in the 
denervated tissue may lead to an increased local 
concentration of the adrenergic transmitters at the smooth 
muscle alpha-adrenoceptor, giving rise to an augmented 
contraction (Aprigliano and Hermsmeyer, 1976).
Scarborough and Carrier (1984) reported that enhanced 
norepinephrine responses of aortas from diabetic rats may be 
related primarily to changes in alpha-2 receptor function. 
They found no differences in the responses to selective 
alpha-1 agonists in aortas of STZ-diabetic rats.
A functional endothelial cell layer is required for the 
vasodilatory effects of several pharmacological agents. 
Removal of the endothelium greatly reduces or ed)olishes 
vascular smooth muscle relaxation induced by these agents. 
The vascular endothelium had been recognized as the 
important site which modulates the vascular smooth muscle 
tone (Furchgott and Zanadski, 1980). Endothelial derived 
relaxing factor (EDRF) , one of the endothelium derived 
substances, has been recognized as an important modulator of 
vascular tone. Recently, endothelin-1 has been identified 
as a 21-residue peptide and shown to be a very potent 
vasoconstrictor (Yanagisawa et a l . 1988) . Ding et al (1991) 
reported that the relaxation response to an endothelium
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
dependent vasodilator, like carbachol, was significantly 
suppressed in diabetic aorta preparations whereas the 
relaxant effect of sodium nitroprusside, which does not 
require a functional endothelium, was not significantly 
changed. This may suggest either disturbances in the 
synthesis or an accelerated destruction of EDRF in the 
diabetic state.
Diabetes Mellitus and Myocardial Functions
Both type of diabetes mellitus are often associated 
with cardiovascular complications such as coronary artery 
lesions and diabetic cardiomyopathy, resulting in a higher 
incidence of myocardial infarction and congestive heart 
failure (Jaffe, 1989). Left ventricular systolic duration 
is abnormal in many diabetics showing no overt evidence of 
coronary heart disease or hypertension (Uusitupa et a l .
1985). In addition to systolic dysfunction, reduced 
diastolic filling rate and a prolonged isovolumic relaxation 
are also frequently observed in diabetes (Pozzoli et a l . 
1984) . Diabetic cardiac dysfunction may be due to 
deterioration of the microcirculation caused by 
abnormalities in vascular sensitivity and reactivity to 
neurotransmitters (Friedman, 1989). Another theory to 
explain cardiac dysfunction suggested by Garber and Neely 
(1983) is that abnormalities in conduction systems alter 
cardiac performance. A  third explanation for cardiac 
dysfunction is due to abnormalities in the myocardium such
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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as depressed myocardial metabolism (Fevury et a l . 1979), 
impaired tissue antioxidant status (Wohaieb and Godin, 1987) 
and decreased sarcolemmal enzyme activity (Pierce et a l , 
1983).
The precise subcellular mechanisms responsible for the 
diabetic cardiomyopathy are unknown. However, it has been 
suggested that elevated myocardial calcium content is 
directly involved in contractile dysfunction and cellular 
necrosis (Pierce, 1988). The mechanism of tissue calcium 
overload is a complex phenomenon, usually involving 
impairment in the movement of calcium by one or more calcium 
transporters (Weir, 1990). In the normally functioning 
myocardium, the sarcoplasmic reticular calcium pump serves 
as the primary mechanism for removal of calcium from the 
cytoplasm. Sarcoplasmic reticular function appears to be 
defective in diabetic myocardium with depressed ATP- 
dependent calcium transport and calcium stimulated ATPase 
activity (Ganguly et a l . 1983). In addition, the diabetic 
myocardium exhibits a variety of abnormalities in 
sarcolemmal ion transport, including depression of Na^-H'*' 
(Pierce et a l . 1990; Lagdic-Gassmann et a l , 1988) and Na+- 
Câ "*" (Makino et a l . 1987) exchange processes and inhibition 
of Ca ATPase (Heyliger et a l . 1987) and Na-K ATPase 
activities (Pierce et a l . 1990).
Diabetes results in several changes in cardiac 
metabolism. The most notable change is decreased glucose
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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transport into muscle cells by f a c u l t a t i v e  glucose 
transporter proteins (GIUT4). A decreased myocardial 
glycolytic flux is also observed in diaübetics due to 
inhibition of the glycolytic enzyme phosphofructokinase.
The activity of this key enzyme is not directly affected by 
diabetes; rather reduced flux through the enzyme occurs 
secondary to the accumulation of citrate, a potent inhibitor 
of phosphof ructokinase (Randle et a l . 1966) .
The role of reactive oxygen radicals in determining 
myocardial ischemia and reperfusion injury (MI/R) now seems 
fairly well established (McCord, 1985; Van der Vusse, 1985) . 
In addition to ischemic heart disease, other complications 
of diabetes suggested by experimental studies to involve 
oxygen radical damage include atherosclerosis (Fogelman et 
a l . 1980), retinal damage (Crouch et a l . 1978) and renal 
injury (Palier et a l . 1984) . Diabetes is known to have 
several effects on antioxidant status (Wohaieb and Godin, 
1987) . The levels of free radicals such as superoxide and 
hydroxyl radicals are controlled by various cellular 
mechanisms consisting of antioxidant enzymes [superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase 
(GSH-PX)/ oxidized glutathione reductase (GSSG-RD) systems] 
and nonenzymatic scavenger components (glutathione, vitamin 
C and vitamin E) (Simmons, 1984). Diabetes is associated 
with significantly increased activities of CAT, GSSG-RD and 
SOD in the pancreas and of CAT and GSSG-RD in the heart. On
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the other hand, the liver of diabetic rats showed a 
generalized decrease in CAT, GSH-PX and SOD as well as in 
the levels of reduced glutathione (GSH). Diabetic kidney 
also showed decreases in CAT and SOD, but the activities of 
GSH-PX were increased. Insulin treatment reversed all of 
the alterations in tissue antioxidant status in Type I 
diabetic animals (Wohaieb and Godin, 1987).
Reperfusion of the myocardium after an ischemic period 
can produce MI/R injury. Reperfusion damage is evidenced by 
a sudden and marked increase in ultrastructural changes, 
enzyme release and calcium influx (Bourdillon et a l . 1981). 
Various mechanisms have been suggested as triggers for 
reperfusion damage including 1) depletion of high energy 
phosphates (Jennings et a l . 1978) and catecholamines (Gaudel 
et a l . 1979), 2) accumulation of calcium (Nay1er, 1981) and 
lysophosphoglycerides (Katz et a l . 1983) and 3) activation 
of phospholipases (Chein et a l . 1980). Whether alterations 
in myocardial metabolism in diabetics have any direct 
effects on MI/R is not clear. Several isolated heart 
studies report that diabetic hearts are more sensitive than 
normal hearts to ischemic injury (Haider et a l . 1977; Palik 
et a l . 1982), but this disparity in sensitivity was 
minimized by increasing the glucose concentration in the 
perfusate (Ingebretsen, 1980) . Vogel and Apstein (1988) 
suggested that diabetic hearts are comparable to normal 
hearts with regard to the severity of MI/R injury. Higuchi
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et al (1990) have shown that diabetic hearts were more 
vulnerable to hypoperfusion damage while normal hearts were 
more susceptible to reperfusion injury. Other reports in 
the literature have demonstrated that diabetic hearts are 
more resistant to ischemic injury than normal hearts (Tani 
and Neely, 1988; Pieper, 1990).
Various mechanisms have been proposed to explain the 
resistance of diabetic hearts to ischemic injury. Shen and 
Jennings (1972a & 1972b) have shown that massive amounts of 
Ca2+ accumulate in ischemic reperfused myocardium. They, 
as well as others, have suggested an association between 
Câ "*" accumulation and irreversible cell damage. Tani and 
Neely (1988) suggested that upon reperfusion Ca^+ uptake was 
less in diabetics than in control and this low accumulation 
of Ca^^ may account for the greater resistance of diabetic 
hearts to ischemia.
Plasma levels of arachidonic acid and prostacyclin have 
been reported to be decreased in diabetic patients 
(Silberbaurer et a l . 1979) as well as in diabetic animals 
(Holman et a l . 1983; Harrison et a l . 1978). Prostacyclin is 
synthesized in response to MI/R injury and Pieper et al 
(1989, 1990) have demonstrated that inhibition of 
prostacyclin synthesis in diabetics increases post-ischemic 
cardiac function.
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Pioglitmmom*:
Thiazolidinediones represent a new structural class of 
anti-diabetic compounds that were discovered empirically by 
observing their hypoglycemic effects in animal models of 
Type II diabetes mellitus (Colca and Morton, 1990). 
Pioglitazone, a representative of such agents, appears to 
lower blood glucose levels in diabetic rodent models through 
a mechanism that involves increased insulin sensitivity in 
target tissues (Colca and Morton, 1990). It increases 
insulin sensitivity by phosphorylation of the tyrosine 
kinase associated with the beta chain of the insulin 
receptor (Kobayashi et a l . 1992).
NH HCI
PIOGLITAZONE HYDROCHLORIDE
Administration of pioglitazone to insulin resistant 
fatty rats results in a dose-dependent decrease in blood 
levels of glucose, triglycerides and insulin (Ikeda et a l .
1990) . Pioglitazone treatment corrects the deficiencies in 
GLUT 4 glucose transporter expression in insulin-resistant
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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obese KKA^ mice (Hofmann et a l . 1991) . This increased
glucose transporter expression resulted despite an 
accompanying reduction of circulating insulin levels.
Glucose transport in mammalian tissues is mediated by a 
family of structurally related, but genetically distinct, 
glucose-transporter proteins. The f a c u l t a t i v e  glucose- 
transporter isoforms have distinct tissue distribution as 
follows: GIUTI in erythrocyte, GLUT2 in liver, 6LUT3 in 
brain, GLUT4 in muscle & fat and GLUTS in small intestine. 
Hofmann et a l . (1992) reported that the two-fold elevation 
in the gluconeogenic enzyme, phosphoenolpyruvate 
carboxykinase (PEPCK) and its mRNA abundance was normalized 
after treatment with pioglitazone.
Sugiyama et al (1990 & 1991) reported that pioglitazone 
treatment reverses all effects in noninsulin dependent 
diabetes mellitus (Type I I), but has no effect on insulin 
dependent diabetes mellitus (Type I) when administered 
alone. The combination of pioglitazone and insulin 
decreased the blood glucose and triglyceride levels in STZ- 
diabetic rats (Hofmann, 1991).
Pioglitazone lowered cholesterol levels in Type I 
diabetic rats fed a high cholesterol diet and produced a 
significant reduction in cholesterol absorption. Drug 
treatment was ineffective in rats that were not given 
dietary cholesterol. The mechanism of the effect on 
cholesterol absorption is unknown. Pioglitazone treatment
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alone did not affect the cholesterol absorption in Type I 
diabetic rats fed a normal diet; however, the combination of 
insulin and pioglitazone synergized to lower absorption of 
cholesterol and circulating cholesterol levels (Colca et a l .
1991).
The effects of pioglitazone on vascular reactivity or 
on vascular changes produced by either Type I or Type II 
diabetes are unknown. Also there are no reports on effects 
of pioglitazone on cardiac function or MI/R injury in either 
healthy or diabetic animals. We have investigated the 
cardiovascular effects of pioglitazone in two models of 
diabetes with the following objectives:
1. To determine the effects of pioglitazone on vascular 
reactivity in Type II diabetes mellitus.
2. To investigate the effects of pioglitazone on vascular 
reactivity in Type I diabetes mellitus.
3. To evaluate the effects of pioglitazone on cardiac 
function and MI/R injury in Type I diabetic animals.
4. To compare the effects of pioglitazone on vascular 
reactivity in both Type I and Type II models of diabetes 
mellitus.
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Male Zucker diabetic fatty rats (Drt-fa) weighing 250 - 
300 g and male Zucker lean rats (nondiabetics) weighing 
250 - 300 g and obtained from Genetic Models, Inc., 
Indianapolis, IN, were used in the Type II diabetes 
mellitus study. Zucker diabetic fatty rats were housed in 
individual wire-mesh cages over woodchip bedding. Two 
Zucker lean rats were housed together in wire mesh cages.
Male Sprague Dawley rats, weighing 250 - 300 g and 
obtained from Bant in & Kingman Co. Fremont, C A . , were used 
in the Type I diabetes mellitus study. Rats were housed in 
individual wire mesh hanging cages. Purina lab chow and 
water were availetble ad lib during 12 hour light-dark 
cycles. All animals were allowed a minimum of 3 to 5 days 
acclimatization before starting the experiments.
Reagents & Drugs:
Reagents and drugs were obtained from the indicated 
sources: Streptozotocin, norepinephrine, carbamyIcholine
chloride, sodium nitroprusside, sodium pyruvate and sodium 
pentobarbital from Sigma Chemical Co. St Louis, MO; sodium 
citrate (Na^CgHgOy • 2H2O ) , sodium chloride (NaCl), 
magnesium sulfate (MgSO^ * 7H2O ) , sodium bicarbonate 
(NaHCO^)r potassium phosphate monobasic (KH2PO4) and ethyl 
ether from Fisher Scientific Co. Fair Lawn, N J ; heparin
14
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from Elkins - Sinn, Inc., Cherry Hill, NJ; calcium chloride 
(CaCl2 * 2H2O) from EH Science, Cherry Hill, NJ; potassium 
chloride (KCl) and glucose from J.T. Baker Chemical Co., 
Phillipsburg, NJ; pioglitazone from Upjohn Co., Kalamazo,
T74MI; Linplant sustained release insulin implant from
Linshin Canada, Ontario, Canada; One Touch^ II Glucose
analyzer kit from Life Scan Co., Milpitas, CA.
EXPERIMENTAL PROTOCOLS 
I. Type XI Diabetes Mellitus Studys
The study focused on vasoreactivity in Type II diabetic 
animals. Diabetic and non-diabetic rats were divided into 
the following groups.
1. Control (C) : Non-diabetic control.
2. Control Pioglitazone (CP): Non-diabetic pioglitazone
treated.
3. Diabetic (D): Diabetic control or untreated.
4. Diabetic Pioglitazone (DP): Diabetic pioglitazone
treated.
A total of nine to eleven rats were used in each 
treatment group. Treatment began at seven weeks of age and 
continued for six weeks with daily dosing (10 mg/kg/day) of 
pioglitazone. Pioglitazone hydrochloride was suspended at 
the concentration of 10 mg/ml in 0.5 M  citrate buffer (pH 
4.5) and was administered by oral gavage to CP and DP group 
rats. Citrate buffer was administered to control and 
diabetic group rats by the same mechanism. All animals were
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
16
weighed daily. Once a week the rats were fasted for five 
hours and blood samples were collected from the distal part 
of the tail. The blood glucose concentration was determined 
with a One Touch^ II glucose analyzer.
At the end of the treatment period, rats were 
anesthetized with sodium pentobarbital (100 mg/kg i.p.).
The thoracic aortas were removed rapidly and dissected free 
of excess fat and connective tissue in Krebs-Henseleit 
solution containing(mM): NaCl 118; KCl 4.7; CaCl2 2.5;
KH2PO4 1.2; HgS04 1.2; NaHCOg 25; Glucose 11. A  part of 
thoracic aorta was cut into transverse ring of 4 mm in 
length and opened longitudinally to prepare 8 X 4  mm strip. 
The aortic strip was attached to an F-60 Myograph (Narco 
Biosystems) to record isometric contraction on a polygraph 
(Narco Biosystems). The tissue was placed in 37^C KH
solution and aerated with 95% 02 and 5% C02 and maintained 
at 37^C. The bath volume was 25 ml. The preparation was
allowed to equilibrate for 30 minutes under an optimal 
resting tension of 1 g. During equilibration the aortic 
strip was washed with fresh solution every 10 minutes.
After equilibration for 30 minutes, contractile 
function of the aortic tissue was examined by replacing the 
K-H solution with a similar solution containing 40 mM KCl. 
After KCl-induced contraction, the aortic strip was washed 
with K-H solution. Washings were repeated every five 
minutes until base line was achieved. Alpha adrenoreceptor-
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mediated contractility was determined by a cumulative 
increase in norepinephrine concentration (lO’^ M  to lO”^
M) in the bath solution. The concentration of the agonist 
in the bath was increased approximately five-fold every 
three minutes. The aortic strip was washed several times 
with fresh K-H solution. A  period of 5-10 minutes was 
allowed for re-equilibration. Voltage dependent 
contractility was then determined by exposure to isotonic K- 
H solution containing 40 mM  and subsequently 100 mM KCl.
The contractile force was expressed in grams.
II. Type I Diabetes Mellitua Studys
This study focused on myocardial and smooth muscle 
function in Type I diabetic rats. Diabetes was induced 
under light ether anesthesia by a single 55 mg/kg body 
weight i.v. injection of streptozotocin (STZ) into the 
jugular vein of 9 week old male Sprague-Dawley rats. 
Streptozotocin was dissolved at a concentration of 55 mg/ml 
in 0.5 M citrate buffer (pH 4.5). Age-matched male rats 
used as control were injected with citrate buffer(pH 4.5). 
Forty-eight rats weighing 250-300 g were used for the study. 
The rats were divided into six groups of eight rats per 
group as indicated below.
1. Control (C): Non-diabetic control.
2. Control Pioglitazone (CP): Non-diabetic pioglitazone
treated.
3. Diabetic (D): Diabetic control.
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4. Diabetic Pioglitazone (DP): Diabetic Pioglitazone
treated.
5. Diabetic Insulin (DI): Diabetic insulin treated.
6. Diabetic Insulin Pioglitazone (DIP): Diabetic insulin and
pioglitazone treated.
Treatment began seven days after injection of STZ or 
citrate buffer and continued with daily dosing of 
pioglitazone(10 mg/kg/day) for six weeks. Pioglitazone 
hydrochloride was suspended at a concentration of 10 mg/ml 
in 0.5 M  citrate buffer (pH 4.5) and administered by oral 
gavage to CP, DP and DIP group rats. Citrate buffer was 
administered to control and diabetic group rats by the same 
mechanism. Sustained release insulin pellets, releasing 
approximately 2 Units of insulin/day, were implanted 
subcutaneously in the back of the neck in the DI and DIP 
groups. All animals were weighed daily and blood glucose 
concentrations were determined as described in the Type II 
study. Whenever the blood glucose levels fell below 30 
mg/dl, ten percent glucose was added to drinking water and 
provided ad lib in replacement of regular drinking water.
The animals which survived the entire treatment period were 
used in the MI/R and vascular reactivity experiments.
At the end of the treatment period, rats were 
anesthetized with sodium pentobarbital (100 mg/kg i.p). They 
were intubated, mechanically ventilated and anticoagulated 
with 200 lU heparin I.V. Hearts were perfused by the aortic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
19
root in situ at 37oo with modified Krebs-Henseleit (K-H) 
solution (112 mM NaCl, 25 mM NaHCO^ # 5 mM K C l , 12 mM MgSO^,
1 mM  KH2PO4, 1.25 mM  CaCl2# 11.5 mM  dextrose, 2 mM sodium 
pyruvate). The perfusate was aerated continuously with 95%
02 and 5% CO2. Hearts were quickly excised and placed in a 
non-recirculating Langendorff apparatus. Coronary perfusion 
was maintained at a constant pressure of 80 mm Hg. A  water 
filled latex balloon attached to a metal intubation tube was 
inserted through the left atrium into the left ventricle and 
connected to a pressure transducer (P 1000b Narco Biosystem) 
to record the left ventricular developed pressure and heart 
rate on a polygraph (MK-III-S,Narco Biosystem) . Hearts were 
allowed to equilibrate for 15 minutes, after which end 
diastolic pressure was adjusted to 5 mm  Hg by inflating the 
balloon. Values for heart rate (HR), left ventricular 
developed pressure (LVDP), coronary flow (CF) and double 
product were determined 20 minutes after inflation of the 
balloon. Heart rate and left ventricular developed pressure 
were recorded from the polygraph. Coronary flow values were 
determined by collecting the coronary perfusate for one 
minute. Cardiac function, estimated as double product, was 
calculated as (HR x LVDP)/1000.
The hearts were then rendered globally ischemic by 
shutting off the flow of modified K-H solution for 20 
minutes. Subsequently, reperfusion with modified K-H 
solution was initiated and maintained for 30 minutes. Final
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values for HR, LVDP, CF and double product were then 
obtained. Rats which did not recover their cardiac function 
after 20 minutes ischemia followed by 30 minutes of 
reperfusion, were not included in the statistical analysis.
Preparation and isolation of thoracic aortas were as 
described in the Type II study with two exceptions. In Type 
I studies aortic rings were used instead of aortic strips 
and two grams of resting tension was used instead of one 
gram. In addition, endothelial dependent and independent 
relaxation was measured using carbachol and sodium 
nitroprusside. The relaxation caused by carbachol in blood 
vessels requires a functional endothelial lining, whereas 
the relaxation produced by sodium nitroprusside is 
independent of the endothelium. Since endothelial dependent 
relaxation is known to be impaired in Type I diabetes, this 
experiment was designed to study the effect of pioglitazone 
treatment on endothelial dependent and independent 
relaxation. Relaxation was assessed by inducing prior 
contraction with norepinephrine (10 M ) . Relaxation 
values were calculated by using the below formula.
Percent relaxation = f M.C. - C.R.R.)
M.C. * ^00
M.C. = Maximal contraction in grams
C.R.R = Contraction in grams after relaxation with either 
carbachol or sodium nitroprusside.
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Statistiom:
The mean and 95% confidence intervals of the EC 50 and 
maximal response to NE were calculated by using the curve 
fitting computer program PC NONLIN. The EC 50 value was 
defined as the concentration of agonist which produced 50% 
of the maximal response. The rest of the data was analyzed 
using Analysis of Variance (ANOVA). Tukey's protected t 
test was used to determine significant differences (P <
0.05).
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RESULTS
Typ# II Model:
The body weights of ZDF rats were significantly greater 
than the non-diabetics. Pioglitazone treatment did not 
affect the body weights of control rats, but did 
significantly increase the body weight of diabetic rats 
(Fig- 1).
Blood glucose levels in the diabetic rats were 
significantly elevated. Pioglitazone treatment 
significantly decreased the blood glucose levels in diabetic 
rats, but blood glucose levels were unaltered in control 
rats (Fig. 2).
Maximal contractile response to NE in aortas from 
diabetic rats was not altered. Pioglitazone treatment 
significantly decreased the maximal response to NE in both 
diabetic and control animals (Fig. 3). The maximal 
contraction and EC 50 values for NE are shown in Table 1.
EC 50 values from diabetic animals were also not altered, 
but EC 50 values were significantly greater in the control 
than the diabetic pioglitazone animals.
No difference was observed between control and diabetic 
aortic maximal contractile response to 40 mM KCl. Diabetic 
rats showed significantly greater maximal contractile 
response than the control pioglitazone (CP) group rats. 
Further depolarization with 100 mM KCl did not produce
22
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greater contractile response, but a similar contractile 
pattern to that seen at 40 mM was observed (Fig. 4) .
Type X Models
During the treatment period D, DP, and DIP groups had a 
mortality rate of 12.5%, 50% and 25% respectively. Because 
of the high mortality rate in DP and DIP groups, the 
experiment was shortened to 40 days instead of 42 days.
The body weights of diabetic rats seven weeks after the 
STZ-treatment were significantly decreased. Diabetic rats 
lost weight initially and never returned to their initial 
weights. Pioglitazone treatment did not affect the body 
weight change in either control or diaüaetic rats. Insulin 
treated diabetic rats gained weight at approximately the 
same rate as control animals, but due to initial weight 
differences they remained lighter throughout the treatment 
period (Fig. 5) .
Blood glucose levels in the diabetic rats were 
significantly elevated. Pioglitazone treatment did not 
affect the blood glucose levels in either control or 
diabetic rats. Insulin normalized the blood glucose levels 
in diabetic animals. When pioglitazone was administered 
along with insulin, the blood glucose levels were 
significantly lower than the diabetic insulin treated group 
at the second and sixth weeks of the study (DI — 111 ± 18 
and DIP = 29 ± 1 mg/dl at week two; DI — 83 ± 15 and DIP = 
44.5 ± 10 mg/dl at week ten). During the final week of the
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Study (week 6) glucose levels in both diabetic groups 
treated with insulin (DI and DIP) increased slightly 
(Fig. 6).
Diaüsetic rats showed elevated glycosylated hemoglobin 
(Hb) values. Pioglitazone treatment did not affect 
glycosylated Hb values either in control or diabetic rats. 
Insulin significantly decreased the glycosylated Hb values 
in diabetic rats. The combined treatment of insulin and 
pioglitazone did not decrease the percentage of glycosylated 
Hb values in diabetic rats (Fig. 7).
The maximal contracti1e response to NE in aortas from 
diabetics was significantly increased. Pioglitazone 
treatment did not alter the maximal response to HE either in 
control or diabetic rats. Although statistical significance 
was not observed, pioglitazone appears to decrease the 
maximal contractile response to NE in CP and DIP groups. 
Insulin treatment did not show any effect on diabetes- 
induced maximal contraction. The combination of insulin and 
pioglitazone treatment decreased the maximal response to NE 
in diabetic rats, but statistical significance was not 
observed (Table 2; Fig. 8).
EC 50 values indicate that control rats were 
significantly more sensitive to NE than the diabetic rats. 
Neither pioglitazone nor insulin showed any affect on EC 50. 
The combined treatment of pioglitazone and insulin decreased 
the EC 50 value in diabetic rats (Table 2).
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Maximal contractile response to KCl in aortas from 
dieü>etic rats was significantly reduced. Administration of 
either insulin or pioglitazone to diabetic animals prevented 
this decrease. However, the combination of insulin and 
pioglitazone (DIP) produced a decreased maximal contractile 
response similar to that seen in the diabetic group 
(Fig. 9).
All concentration response curves for the carbachol- 
induced relaxation of rat aortas were shifted to the right 
of the control. There were, however, no significant 
differences observed in the maximal relaxation between 
control and the D and DI groups. Pioglitazone treatment 
significantly decreased the maximal relaxation in the 
control group. Although significant differences were not 
observed, pioglitazone appeared to decrease maximal 
relaxation in the DP and DIP groups (Fig. 10).
No significant differences were observed in the maximal 
endothelial-independent relaxation of aortic tissue to 
sodium nitroprusside (Fig. 11).
Pre-ischemic cardiac Functions
Although statistical significance was not observed, 
heart rate tended to be reduced in diabetic rats. 
Pioglitazone treatment significantly decreased the heart 
rate in diabetic rats. Insulin treatment normalized the 
heart rate in diabetic rats. The combination of insulin and 
pioglitazone treatment demonstrated higher heart rates than
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pioglitazone treatment alone, but not as high as insulin 
treatment (Table 3) .
Diabetic rats showed no change in left ventricular 
developed pressure. However, diabetic groups without 
insulin treatment showed a tendency for lowered LVDP.
Neither pioglitazone nor insulin treatment significantly 
increased the LVDP, but the combination of insulin and 
pioglitazone treatment significantly increased the LVDP in 
diabetic rats (Table 3).
Pre-ischemic double product was significantly lower in 
D and DP groups compared to all other groups. Pioglitazone 
significantly increased the double product in the control 
group. Insulin treatment and the combination of insulin and 
pioglitazone treatment normalized the double product in 
diabetic rats (Table 3).
Diabetic rats had significantly reduced coronary flow. 
Pioglitazone treatment did not alter the coronary flow in 
either control or diabetic rats. Although statistical 
significance was not observed, insulin treatment and the 
combination of insulin and pioglitazone treatment appeared 
to normalize the coronary flow in diabetic rats (Table 3). 
MI/R Injury:
After 20 minutes of ischemia followed by 30 minutes of 
reperfusion, all hearts showed measurable cardiac function 
in D, DP and DI groups. C, CP and DIP group hearts showed 
measurable cardiac function in only seven out of eight, five
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out of eight and four out of six, respectively (Table 4). 
Only hearts that recovered to some degree were used in the 
statistical analysis.
Post-ischemic heart rate was not different from pre- 
ischemic heart rate in all groups. Diabetic rats showed no 
change in the percentage of post-ischemic recovery of heart 
rate. Neither pioglitazone nor insulin showed any effect on 
post-ischemic recovery of heart rate. The combination of 
insulin and pioglitazone treatment (DIP) significantly 
reduced the post-ischemic recovery of heart rate in diabetic 
animals (Table 4) .
Post-ischemic left ventricular developed pressure was 
significantly reduced in all groups except, DP. Diabetic 
rats showed no change in the percentage of post-ischemic 
recovery of LVDP. Neither pioglitazone nor insulin 
treatment showed any effect on post-ischemic recovery of 
LVDP. The combination of insulin and pioglitazone treatment 
(DIP) significantly diminished post-ischemic recovery with 
respect to the DP group (Table 4) .
Post-ischemic recovery of double product was 
significantly reduced in all groups except DP. There is no 
significant difference between diabetic and control rats. 
Neither pioglitazone nor insulin treatment showed any effect 
on post-ischemic recovery of double product. The 
combination of insulin and pioglitazone treatment (DIP) also 
did not show any effect on double product (Table 4) .
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Post-ischemic coronary flow was significantly reduced 
in all groups except DP and DI. Diabetic rats showed no 
change in the percentage of post-ischemic recovery of the 
coronary flow. Neither pioglitazone nor insulin treatment 
showed any effect on post-ischemic recovery of coronary 
flow. The combination of insulin and pioglitazone treatment 
(DIP) significantly diminished post-ischemic recovery with 
respect to the DI group (Table 4) .
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Fig. 1. Effect of pioglitazone on body weight in Type II diabetic rats. 
C — Control: CP - Control pioglitazone treated; D — Diabetic; DP — 
Diabetic pioglitazone treated.
CP and DP group rats received pioglitazone (10 mg/kg/day) by oral gavage 
from 0 - 6  weeks.
Each point represents means of 9-11 rats.* Significantly different from all other groups at week 6.
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Fig. 2. Final week blood glucose levels in Type II diabetic rats All values are expressed as Mean ± SE.
* Significantly different from all other groups.
See Fig. 1 for description of treatment groups.
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Fig. 3. Effect of pioglitazone on vascular reactivity to norepinephrine 
in Type II diabetic rat aortic strips.Each point represents mean of 9 - II experiments.# Significantly different from respective control group.
See Fig. 1 for description of treatment groups.
N - 9, 10, 10, 11 for groups C, CF, D, DP respectively.
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Table 1. Maximal contractile response and EC 50 values 
of NE in aortas from Type II diabetic rats.
1 Group Maximal Response(g) 
( 95% C.I.)
EC 50 (nM) 
(95% C.I.)
1 ^
1 (N = 9)
1.41 ± 0.4 
(1.31 - 1.51)
8.31 ± 1.7 
(4.77 - 11.84) 1
CP
(N = 10)
1.15 ± 0.4 ^ 
(1.05 - 1.24)
4.31 ± 1.1 1 
(2.02 - 6.6) 1
D
(N = 10)
1.56 ± 0.06 
(1.44 - 1.68)
4.87 ± 1.2 1 
(2.43 - 7.3)
DP
(N = 11)
1.27 ± 0.05  ̂
(1.17 - 1.37)
2.29 ± 0.6  ̂
(1.0 - 3.59)
Data are presented as Mean ± SE with 95% confidence 
intervals in the parentheses.
Maximal response is expressed in grams of tension.
EC 50 values are expressed as bath concentration (nM) which 
produced 50% maximal response.
C = Control; CP = Control Pioglitazone; D - Diabetic; DP = 
Diabetic Pioglitazone.
1 significantly lower than respective untreated group.
2 Significantly lower than control (C).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
C P
33
D  E ü l  D P
O)
o
coy  1 -
UJ
4 0  m M 100 m M
Fie. 4. Maximal contractile response of rat aortic strip to 40 mM and 100 mM KCl.
All values are expressed as Mean ± SE.
* Significantly different from CP group.
See Table 1 for description of treatment groups and N values.
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Fig, 5. Mean body weights in Type I diabetic rats.
C — Control; CP — Control pioglitazone treated ; D — Diabetic; DP — 
Diabetic pioglitazone treated; DI - Diabetic insulin treated; DIP — Both 
insulin and pioglitazone treated diabetic group.
N values: C - 8; CP - 8; D - 7; DP - 4; DI - 8; DIP - 6.
Streptozotocin <55 mg/kg) given intravenously to D, DP, DI and DIP 
groups at week 0.
Pioglitazone (10 mg/kg/day) given by oral gavage to CP, DP and DIP 
groups from week one to seven.
Sustained release insulin pellets, releasing approximately 2 U/day for 
40 days, were implanted s.c. at week one to DI and DIP groups.
* C & CP are significantly different from all other groups at week 7.
# DI & DIP are significantly different from all other groups at week 7.
$ D & DP are significantly different from all other groups at week 7.
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Fig. 6. Mean blood glucose levels in Type I diabetic rats.
See Fig. 5 for description of treatment groups and N values.
$ DI is significantly different from all groups at week 2.
* D and DP are significantly different from all other groups at 
week 6.# DI is significantly different from D, CP, DP and DIP groups at 
week 6.
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Fig. 7. Glycosylated hemoglobin values after 6 weeks in Tvoe I diabetic rats. All values expressed as Mean ± SE.* Significantly different from C, CP and DI groups.
See Fig. 5 for description of treatment groups and N values
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Table 2. Maximal contractile response and EC 50 values 
of NE in aortas from Type I diabetic rats.
Group Maximal Response (g) 
( 95% C.I.)
EC 50 (nM) 1 
(95% C.I.) 1
C
(N = 7)
1.15 ± 0.07 
(1.00 - 1.31)
* 0.83 ± 0.44 1 
(-0.06 - 1.72) 1
CP
(N = 7)
1.08 ± 0.08 
(0.91 - 1.25)
4.15 ± 2.24 1 
(-0.4 - 8.72) 1
D
(N = 6)
1.54 ± 0.06  ̂
(1.41 - 1.61)
8.56 ± 2.25  ̂
(3.93 - 13.18)
DP
(N = 4)
1.65 ± 0.15  ̂
(1.32 - 1.98)
. 2.23 ± 1.58 
(-1.1 - 5.55)
DI
(N = 8)
1.53 ± 0.13  ̂
(1.27 - 1.80)
. 6.56 ± 3.73 
(-0.9 - 14)
DIP 
--- (N = 5)
1.34 ± 0.06 
(1.20 - 1.47)
1.42 ± 0.5 
(0.37 - 2.47)
Data are presented as Mean ± SE with 95% confidence 
intervals in the parentheses.
Maximal response is expressed in grams of tension.
EC 50 values are expressed as bath concentration (nM) 
which produced 50% maximal response.
* 95% confidence intervals overlap zero.
See Fig. 5 for explanation of treatment groups.
1 Significantly different from C and CP groups.
2 Significantly different from CP group.
3 Significantly different from C and DIP.
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Fig. 8. Effect of pioglitazone on vascular reactivity to norepinephrine in Type I diabetic rat aortic rings.See Fig. 5 for explanation of treatment groups.
N Values and significant differences are shown in Table 2.
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Fig. 9. Maximal contractile response of Type I diabetic rat aortic ring 
to 40 mM KCl.
All values are expressed as Mean ± SE.
See Fig. 5 for description of treatment groups.
N values are shown in Table 2.
* Significantly different from C, DP and DI groups.
# Significantly different from DI group.
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Fig. 10. Relaxant response of Type 1 diabetic rat aortic ring to carbachol.
* Significantly different from C, D amd DI at maximal dose.N values are shown in Table 2.
See Fig. 5 for description of treatment groups.Percent relaxation = ( M.C. - C.R.R.) v n nnM.C.M.C.= Maximal contraction in grams.
C.R.R.= Contraction in grams after relaxation with either carbachol or sodium nitroprusside.
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Fig. 11, Relaxant, response of Type I diabetic rat aortic ring to sodium nitroprusside.
Terms and abbreviations are same as Fig. 10.
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Table 3. Pre-ischemic cardiac function in Type I 
diabetic rats.
HR LVDP Double CF
(beats/Min) (mm Hg) Product (ml/Min)
c 240 94 22.3 15.6
(N=8) ± 10 ± 4 ± 0.8 ± 0.5
CP 258 108 27.8 ^ 17
(N=8) ± 9 ± 10 ± 2.6 ± 0.5
D 210 ^ 79 ® 16.5 ® 12 *
(N=7) ± 10 ± 8 ± 1.4 ± 1.7
DP 2150 82 11.2 ® 11 ^
(N=4) ± 34 ± 12 ± 1.2 ± 2.4
DI 250 91 22.9 14 ^
(N=7) ± 7 ± 5 ± 1.7 ± 0.5
DIP 224 106 23.3 14.6
(N=6) ± 8 ± 10 ± 1.6 ± 0.8
Data are presented as Mean ± SE.
H R  = Heart Rate, LVDP = Left Ventricular Developed Pressure, 
CF = Coronary Flow, Double Product = (HR X LVDP)/1000.
See Fig. 5 for description of treatment groups.
1 Significantly different from DI and CP groups.
2 Significantly different from all other groups.
3 Significantly different from C and CP groups.
4 s= Significantly different from C, CP and DIP groups.
5 S igni f icantly different from CP group.
6 = Significantly different from CP and DIP groups.
7 Significantly different from Control.
8 Significantly different from C, CP, DI and DIP groups.
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Table 4. Post-ischemic cardiac function in Type I 
diabetic rats.
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FR HR LVDP Double
Product
CF
C 7/8 92 53 ^ 49 ^ 68 ^
(N-7) ± 4 ± 8 ± 6 ± 3
CP 5/8 90 65 59 ^ 76 ^
(N=5) ± 3 ± 4 + 4 ± 5
D 7/7 98 56 ^ 56 ^ 81 "
(N-7> ± 2 ± 6 ± 7 ± 6
DP 4/4 87 72 ^ 64 ^ 79
(N=4) + 5 ± 10 ± 12 ± 2
DI 7/7 92 44 ^ 40 ^ 92
(N=7) ± 4 ± 3 ± 4 ± 18
DIP 4/6 86 ^ 48 ^ 42 1 56
(N=4) ± 3 ± 8 ± 8 ± 5
All values are expressed as percent of mean ± SE of pre- 
ischemic values except FR.
FR = Fraction of hearts demonstrating measurable 
postischemic cardiac function; HR= Heart Rate; CF= Coronary 
Flow; LVDP = Left Ventricular Developed Pressure;
See Fig. 5 for description of treatment groups.
1 = Significantly different from respective pre-ischemic 
v alue•
2 = Significantly different from Diabetic (D) group.
3 * Significantly different from DI and DIP groups.
4 — Significantly different from DI
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Discnssioif 
Type IX diabetea mellitua:
Pioglltazone increased the body weight in Type II 
diabetic animals, but did not alter the body weight in non­
diabetic controls (Fig 1). Hofmann et a l . (1991) provided
evidence that after four days of pioglitazone treatment, 
body weights were increased, although insignificantly, in a 
dose dependent manner in diabetic KKA mice. In a similar
study with Wistar diabetic fatty rats, after seven days of 
pioglitazone treatment, the body weight was increased 
concomitant with an increase in food intake (Sugiyama et a l . 
1990). These effects of pioglitazone were very prominent in 
hyperinsulinémie (Type II) animals, but not observed in 
either normoinsulinemic (control) or hypoinsulinemic (Type 
I) animals (Ikeda, 1990; Hofmann et a l . 1991). This 
phenomenon seems to be caused by an insulin potentiating 
effect of pioglitazone.
Peterson et al (1990) reported that the average blood 
glucose levels of ZDF rats were above 500 mg% by 12 weeks of 
age and remained high. Although our experiments with ZDF 
rats were conducted for 14 weeks, the average blood glucose 
levels were much lower (268 ± 31 m g % ) . It is unclear why 
there was a difference. Pioglitazone treatment decreased 
the blood glucose levels in insulin resistant Type II 
diabetic animals, but did not alter the blood glucose levels 
in control rats (Fig. 2). This work is consistent with the
44
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previous report in which pioglitazone decreased the blood 
glucose levels in Type II diabetic animals, but had no 
effect in control animals (Colca and Norton 1990) •
The results of the present study indicate that the 
maximal contractile response to NE and KCl in aortas from 
Type II diabetic rats was not significantly different from 
nondiabetics (Fig. 3 & 4; Table 1). Although statistical 
significance was not observed, maximal contractile response 
to NE and KCl appeared to be somewhat higher in diabetics 
(D). Our diabetic animals had blood glucose values in the 
moderately diabetic range (268 ± 31 m g%), rather than being 
highly diabetic range (500 m g % ) . This reduced diabetic 
state, with respect to blood glucose, could explain why no 
significant difference was observed between control and 
diabetic animals. No reports have been found in the 
literature on the maximal contractile response to NE and KCl 
in Type II diabetic animals. Pioglitazone treatment 
significantly decreased the maximal response to NE in both 
control and Type II diabetic animals. This implies that 
pioglitazone decreased the maximal contractile response to 
NE independent of diabetic state.
Type I Diabetes Mellitus:
When pioglitazone, at a dose of 10 mg/kg/day, was given 
orally to Type I diabetic animals (DP) for 40 days, an 
overall rate of 50% mortality was observed in this 
experiment. The remaining rats were also lethargic and
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developed severe diarrhea. Pioglitazone treatment did not 
alter either body weight or blood glucose levels in Type I 
diabetic animals. DP group glycosylated hemoglobin values 
also showed no change when compared with diabetic (D) group. 
Pioglitazone administered to diabetic rats (DP) showed the 
highest moirtality and the lowest values of heart rate, LVDP, 
coronary flow and double product. In addition, DP group 
showed the highest maximal contractile response to NE among 
the treatment groups. These results suggests that long term 
treatment of pioglitazone may be highly deleterious to 
hypoinsulinemic (Type I) diabetic animals.
Both untreated and pioglitazone treated control animals 
increased body weight significantly over the six weeks of 
the experiment (Fig. 5) . The induction of diabetes with STZ 
appeared to inhibit the normal increase in body weight 
observed in control animals. Those diabetic animals treated 
with either insulin or pioglitazone and insulin also 
increased body weight. These DI and DIP group rats, 
however, had a significantly lower body weight than either 
of the control groups. The D and DP groups showed no 
increase in body weight throughout the experimental period. 
Our observations are similar to previous work with STZ- 
induced diabetic rats (Hofmann et a l . 1991). In the present 
study, coronary flow and double product were depressed in 
hearts of Type I diabetic animals. The possibility must be 
considered that this difference may have resulted from the
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smaller body weight of diabetic rats. Penpargkul et al
(1980) conducted an experiment to determine the effect of 
body weight and heart size on cardiac performance. This 
experiment involved two sets of small hearts designed to be 
similar in weight to hearts of diabetic rats, food 
restricted rats and younger rats. Unlike hearts of diabetic 
animals, these two sets of hearts from nondiabetic rats did 
not exhibit depressed cardiac performance. Although we did 
not measured the heart weights, taking into consideration 
the above results, it would appear that the potentially 
smaller size of hearts in STZ -treated animals can not 
account for the depressed cardiac performance.
Pioglitazone did not decrease the blood glucose levels 
in Type I diabetic animals. When pioglitazone was 
administered along with the insulin, blood glucose levels 
were significantly lower than insulin treated diabetic 
animals only at the second and sixth weeks of the study 
(Fig. 6). At the second week, insulin treatment alone 
decreased the blood glucose levels to 111 ± 18 mg% whereas 
the combination of insulin and pioglitazone treatment 
decreased the blood glucose levels to 29 ± 1 mg% in Type I 
diabetic animals. These results clearly demonstrate the 
synergistic effect of insulin and piolgitazone in Type I 
diabetic animals. Because of hypoglycemia in DIP group, 
starting from the second week to fifth week, ten percent 
glucose water was supplemented ad lib instead of normal
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drinking water. Due to glucose supplementation to DIP group 
animals, significant difference was not observed from third 
to fifth week. After the fifth week, the effectiveness of 
insulin pellets appears to be decreased. Blood glucose 
levels were increased in two groups that received insulin. 
This phenomenon again showed the additive effect of insulin 
and pioglitazone by showing the significant difference 
between DI and DIP groups. These results are in agreement 
with those of Hofmann et al (1991), who demonstrated that 
the combination of insulin and pioglitazone decreased the 
blood glucose levels in Type I diabetic animals. These 
findings again indicated that pioglitazone has antidiabetic 
effects, but only when administered along with insulin.
Type I diabetic rats showed elevated glycosylated Hb 
values. Insulin treatment normalized the glycosylated Hb 
values in diabetic animals. Pioglitazone treatment did not 
alter the glycosylated Hb values either in control or 
diabetic animals. Combination of insulin and pioglitazone 
also did not decrease the glycosylated Hb values in the DIP 
group (Fig.7). If the blood glucose is chronically elevated 
(>115 mg%) , a variety of body proteins, including HbA, can 
be nonenzymatical ly glycosylated by means of glucose 
interacting with a free amine in a protein resulting in a 
Schiff-Base aldimine with subsequent formation of a stable 
product in an Amadori rearrangement. A possible explanation 
for the elevated glycosylated Hb levels seen in the DIP
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group could be that the synergistic effect of insulin and 
pioglitazone might not reverse the Amadori rearrangement of 
glycosylated proteins.
Reports in the literature describe increased (White 
al 1990) and decreased (Fulton et al 1991? Ramanadhan et al 
1984) vascular reactivity to NE in Type I diabetic animal 
models. Our results are in agreement with those of White @6 
al (1990), which demonstrated increased vascular reactivity 
to NE in Type I diabetic animals (Table 2? Fig. 8). 
Pioglitazone did not alter the maximal contractile response 
to NE either in control or diabetic animals. The 
combination of pioglitazone and insulin treatment appears to 
decrease the maximal response to NE in Type 1 diabetic rats, 
but statistical significance was not achieved. Insulin 
treatment did not show any effect on Type I diabetes-induced 
increased maximal contraction. In contrast, Pfaffman et al
(1981), reported that insulin treatment completely reversed 
the diabetic-induced decrease in vascular contractility to 
NE.
The KCl-induced maximal contractile response was 
decreased in Type I diabetic animals. These results are 
consistent with a previous report in which KCl-induced 
maximal contractile response was decreased in Type I 
diabetic animals (Fulton et a l . 1991). Insulin treatment 
normalized the vascular reactivity to KCl in Type I diabetic 
animals. Our results are in agreement with Pfaffman et al
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1982, who demonstrated that diabetes-induced decrease of KCl 
contraction is completely reversible by insulin treatment. 
Pioglitazone treatment also normalized the vascular 
reactivity to KCl in Type I diabetic animals. This effect 
however was not observed when insulin and pioglitazone were 
used in combination (Fig. 9).
Ding et al (1991) reported that the endothelial 
dependent relaxation produced by carbachol in aortic rings 
pre-contracted with NE was reduced in Type I diabetic rats. 
Although statistical significance was not observed, our 
results show decreased maximal relaxation to carbachol in 
Type I diabetic animals (Fig. 10). These results suggest 
that deterioration of the endothelium might exist in 
diabetic rats. Pioglitazone treatment decreased the maximal 
relaxation to carbachol in all pioglitazone treatment 
groups, but only the CP group was significantly lower than 
the C, D and DI groups. These results indicate that 
pioglitazone may alter the endothelial function 
independently of diabetes or insulin. On the other hand, 
endothelial independent relaxation was not altered either 
with the diskbetic state or with pioglitazone treatment. 
Endothelial independent relaxation results are in agreement 
with Ding et al (1991), who demonstrated no significant 
differences due to diabetes (Fig. 11). No previous reports 
are available on the effect of pioglitazone on endothelial 
independent relaxation.
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Type I diabetic hearts showed no change in heart rate 
(Table 3). This result is consistent with the previous 
reports in which heart rate was unaffected in diabetic 
animals (Pieper 1990; Vogel and Apstein 1988) . LVDP also 
was not altered in diabetic hearts, but there was a tendency 
for reduced LVDP in diabetic hearts (Ta&ble 3) . Vogel and 
Apstein (1988) and Tani and Neely (1988) found no change in 
LVDP; whereas, Ingebretsen et al (1980) found significantly 
decreased LVDP in Type 1 diabetic hearts. Although diabetic 
heart rate and LVDP were not significantly lower when 
compared with control, double product which is the best 
estimate of cardiac function, showed a significant decrease. 
In agreement with our results, Tani and Neely (1988) also 
found decreased double product in Type I diabetic rats. 
Coronary flow was significantly decreased in diabetic 
animals (Taüale 3) . In contrast, Ingebretsen et al (1980) 
found no change in coronary flow.
Pioglitazone treatment significantly decreased the 
heart rate, coronary flow and double product in Type I 
diabetic animals, while pioglitazone increased the double 
product in control animals (Table 3). Moreover, 
pioglitazone treatment did not show any deleterious effects 
on heairt rate, LVDP and coronary flow in control animals. 
These results suggests that pioglitazone treatment may be 
harmful only in the absence of insulin. There are no 
previous reports available in the literature on the effects
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of pioglitazone on cardiac performance in either Type I or 
Type II diabetic animals. Insulin treatment normalized the 
heart rate, LVDP, coronary flow and double product in 
diabetic hearts. In agreement with our results, several 
authors have shown in animal studies and in isolated 
preparations that insulin increased the cardiac performance 
in Type I diabetic animals (Lucchesi et al 1972; Lee and 
Downing 1976) . The combination of insulin and pioglitazone 
treatment showed the synergistic effect by normalizing the 
LVDP and double product in diabetic rats.
The results of the present study show that STZ-induced 
diabetic rats did not show any increased resistance to MI/R 
injury (Table 4) . Tani and Neely (1988) demonstrated that 
when whole heart ischemia was maintained for 30 minutes 
followed by 30 minutes reperfusion at 37*^C, diabetic hearts
completely (101 ± 12%) recovered their cardiac function 
whereas hearts from the control animals recovered only 40 ± 
6% of their pre-ischemic cardiac function. In contrast, our 
results shows that when hearts were rendered ischemic for 20 
minutes followed by 30 minutes reperfusion, dieüoetic hearts 
recovered 56 ± 7% of their cardiac function whereas hearts 
from control animals recovered 49 ± 6% of their pre-ischemic 
function (Table 4) . Our results are in agreement with those 
of Vogel and Apstein (1988), who demonstrated that diabetes 
did not alter the severity of MI/R injury in isolated heart 
preparations. On the other hand, previous studies of the
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isolated heart suggest that diabetic hearts are more 
sensitive to ischemic or anoxic injury (Fevury et al 1980; 
Ingebretsen 1980). In these studies, ischemic or anoxic 
injury was not followed by reperfusion.
Pioglitazone increased the post-ischemic recovery of 
LVDP and double product when compared to the DI group. 
However, pioglitazone demonstrated deleterious effects on 
pre-ischemic cardiac function. Pioglitazone treatment made 
animals very sick and caused severe diarrhea. Insulin 
treatment did not show any effects on post-ischemic recovery 
of heart rate, LVDP, double product or coronary flow in Type 
I diabetic animals. In contrast, Tani and Neely (1988) 
demonstrated that insulin treatment decreased the resistance 
to MI/R injury in Type I diabetic animals. Our results 
demonstrated that the combination of insulin and 
pioglitazone treatment significantly reduced the post­
ischemic recovery of heart rate, but did not show any 
effects on post-ischemic recovery of LVDP, double product or 
coronary flow in Type I diabetic animals. These results 
suggest that the combination of insulin and pioglitazone 
treatment may be deleterious to postischemic heart rate. 
Comparison of Type X and Type II Diabetes Mellituss
Type I diabetic rats show decreased body weight, but 
body weight was increased in Type II diabetic rats. 
Pioglitazone treatment did not alter the body weight in 
either Type I diabetic or control rats, but Type II diabetic
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rat body weights were significantly increased.
Pioglitazone treatment alone did not show any effect on 
blood glucose levels in either Type I diabetic or control 
rats. When administered along with insulin, pioglitazone 
showed a synergistic effect by decreasing the blood glucose 
levels in Type I diabetic animals. In Type II diabetes, 
pioglitazone significantly decreased blood glucose levels. 
Hofmann et al (1991) reported that GLUT4 transporter 
proteins and their mRNA expression were decreased in both 
Type I and Type II diabetic animal models. Treatment of both 
types of diabetic animals with pioglitazone corrects the 
deficits in glucose transport, 6IUT4 mRNA and protein 
levels. Treatment with pioglitazone alone is sufficient for 
correction of glucose transport in Type II diabetic animals, 
but hypoinsulinemic animals require insulin therapy along 
with pioglitazone treatment for similar correction. Since 
insulin and pioglitazone seem to work synergistically, it is 
likely that pioglitazone acts to amplify cellular responses 
to insulin (Fig. 6).
Type I diabetic rats showed increased contractile 
response to NE, but Type II diabetic rats did not show any 
change in maximal contractile response to NE. Pioglitazone 
decreased the maximal response to NE in both Type II 
diabetic and Zucker nondiabetic rats, but did not show any 
effect in either Type I diabetic or nondiabetic Sprague 
Dawley rats. It is possible that the decrease in maximal
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contractile response to NE with piogl itazone treatment may 
be species related.
KCl-induced maximal contractile response was decreased 
in Type I diabetic rats, but not altered in Type II diabetic 
rats. Pioglitazone increased the maximal response to KCl in 
Type I diabetic rats, but did not alter the maximal response 
to KCl in Type II diabetic rats, 
conclusions
Pioglitazone treatment increased the body weight and 
decreased the blood glucose levels in Type II diabetic 
animals, but did not alter either body weight or blood 
glucose levels in control and Type I diaibetic animals. 
Pioglitazone treatment did not alter the glycosylated Hb 
values either in control or Type I diabetic rats. Maximal 
contracti1e response to NE and KCl was decreased by 
pioglitazone in Type II diabetic and control animals.
In Type I diabetic animals, maximal contractile 
response to KCl was decreased with pioglitazone treatment, 
but maximal contractile response to NE was unaltered. The 
combination of insulin and pioglitazone or insulin alone did 
not show any effects on maximal contractile response to NE. 
Pioglitazone treatment decreased the endothelial dependent 
relaxation in control animals, but endothelial independent 
relaxation was unaltered in both control and diabetic rats. 
Coronary flow and double product were decreased in Type I 
diabetic animals. Pioglitazone administered to diabetic
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rats (DP) showed the highest mortality and the lowest values 
of heart rate, LVDP, coronary flow and double product. 
Insulin treatment normalized the cardiac function in Type I 
diabetic animals, and also, the combination of insulin and 
pioglitazone treatment normalized the LVDP and double 
product in Type I diabetic animals. The results of the 
present study suggests that the severity of MI/R injury is 
identical in both Type I diabetic and control animals. 
Neither pioglitazone nor insulin treatment protected against 
MI/R injury in either control or diabetic rats.
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